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Abstract
Targeting subunits of BAF/PBAF chromatin remodeling complexes has been proposed as an approach to exploit
cancer vulnerabilities. Here we develop PROTAC degraders of the BAF ATPase subunits SMARCA2 and SMARCA4
using a bromodomain ligand and recruitment of the E3 ubiquitin ligase VHL. High-resolution ternary complex
crystal structures and biophysical investigation guided rational and efficient optimization towards ACBI1, a potent
and cooperative degrader of SMARCA2, SMARCA4 and PBRM1. ACBI1 induced antiproliferative effects and cell
death caused by SMARCA2 depletion in SMARCA4 mutant cancer cells,  and in acute myeloid leukemia cells
dependent on SMARCA4 ATPase activity. These findings exemplify a successful biophysics- and structure-based
PROTAC design approach to degrade high profile drug targets and pave the way towards new therapeutics for the
treatment of tumors sensitive to the loss of BAF complex ATPases.
Introduction
Proteolysis targeting chimeras (PROTACs) are an emerging new class of drug molecules wherein a target-
binding ligand linked covalently to an E3 ligase-binding ligand forms a target-PROTAC-ligase ternary complex,
directing the ubiquitin proteasome system to degrade the target protein1-3. In contrast to classical small molecule
drugs,  PROTAC-driven  degradation  functions  in  a  sub-stoichiometric  nature  thus  requiring  lower  systemic
exposures to achieve efficacy4, 5. PROTACs have been shown to display higher degrees of selectivity for protein
degradation than the target ligand itself due to complementarity differences in the protein-protein-interaction
interfaces of the formed ternary complexes6-9. In addition, PROTACs promise to expand the druggable proteome
as degradation is  not limited to the protein domain functionally  responsible for  the disease.  In the case of
challenging multidomain proteins, traditionally viewed as undruggable targets, the most ligandable domain can
be targeted for degradation independent of its functionality or vulnerability to small molecule blockade10, 11. 
The ATP-dependent activities of the BAF (SWI/SNF) chromatin remodeling complexes affect the positioning
of  nucleosomes  on  DNA  and  thereby  many  cellular  processes  related  to  chromatin  structure,  including
transcription, DNA repair and decatenation of chromosomes during mitosis12, 13. The BAF complex is mutated in
approximately  20%  of  human  cancers  and  contains  one  of  two  mutually  exclusive  ATPases,  SMARCA2  or
SMARCA413-16. While SMARCA4 acts as a tumor suppressor in solid tumors, the role of SMARCA4 in acute myeloid
leukemia (AML) is markedly different, such that it is required to maintain the oncogenic transcription program
1
Accepted Manuscript version of Farnaby, William et al. "BAF complex vulnerabilities in cancer demonstrated via structure-based 
PROTAC design". Nature Chemical Biology. 2019. https://doi.org/10.1038/s41589-019-0294-6
and drive proliferation17. Selective suppression of SMARCA2 activity has been proposed as a therapeutic concept
for SMARCA4-mutated cancers18-20. A recent disclosure by Papillon  et al. (published while this manuscript was
under review) demonstrated that dual allosteric inhibitors of SMARCA2/4 ATPase activity show anti-proliferative
effects in a SMARCA4 mutant xenograft model21.
Small molecule ligands targeting the bromodomains of SMARCA2 and SMARCA4 (SMARCA2BD/SMARCA4BD)
have also been reported18, 22, 23. Although cells lacking SMARCA4 activity are vulnerable to the loss of SMARCA218,
SMARCA2/4BD inhibitors  have  failed  to  phenocopy  these  anti-proliferative  effects.  Indeed,  re-expression  of
SMARCA2  variants  in  cells,  where  the  endogenous  protein  had  been  suppressed,  showed  that  an  intact
bromodomain is not required to maintain proliferation24. SMARCA2/4BD inhibitors are thus precluded from use
for the treatment of SMARCA4 mutant cancers but could provide attractive ligands for PROTAC conjugation.
Small molecules binding to other bromodomains have been successfully converted into PROTACs by conjugating
them with structures capable of binding to the E3 ligases VHL or cereblon 5,  6,  10,  11,  25-27. In the case of the BET
protein BRD4, this has been achieved through the use of structure-based drug design via ternary complex crystal
structures7. We therefore reasoned that a PROTAC targeting the non-functional bromodomain of SMARCA2/4
should offer an opportunity to exploit the vulnerability of SMARCA2- or SMARCA4-dependent cancer cells for
therapeutic purposes.
Here we show how structure-based PROTAC design enabled the identification of  a  potent  degrader of
SMARCA2  and  SMARCA4  with  anticancer  activity.  Biophysical  analysis  identified  a  prototype  that  forms
cooperative  ternary  complexes,  electing  it  as  a  lead  for  further  investigation.  Co-crystallization  of  ternary
complexes guided rational design to yield an optimized chemical probe, ACBI1, in only two design steps. With
this  compound we  demonstrate  how depletion of  the  ATPases  can  lead  to  a  reduction in  other  BAF/PBAF
subunits within these stable complexes due to dissociation following SMARCA2/4 depletion. Furthermore, rapid
and  profound  PROTAC-induced  knockdown  of  SMARCA2/4  led  to  pronounced  anti-proliferative  effects  and
apoptosis across multiple cancer cell lines, substantiating the potential of targeted degradation of BAF complex
ATPases as a viable cancer therapeutic strategy.
Results
Identification of a partial SMARCA2/4 degrader
In order to identify a targeted SMARCA degrader we first looked to select a suitable binding ligand. Great
effort has been applied to discover SMARCA bromodomain inhibitors, so we turned our attention to a series of 2-
(6-aminopyridazin-3-yl)phenols reported to possess robust SMARCA2/4 binding22, 28, 29. To elucidate the binding
mode of these ligands and guide PROTAC conjugation design, we solved the co-crystal structure of a piperazine
substituted SMARCABD ligand (1) with SMARCA2BD (Fig. 1a, Supplementary Table 1, PDB ID: 6HAZ). The observed
binding mode is characterized by an interaction deep in the acetyl-lysine binding site between the phenol of the
ligand and Y1421 as well as a donor/acceptor interaction between the aminopyridazine core and N1464. The
piperazine ring of the ligand protrudes out into the solvent, suggestive of a suitable vector for PROTAC linkage. To
recruit the  von Hippel−Lindau (VHL) E3 ubiquitin ligase, we chose a VHL ligand with high affinity and known
binding mode, recently published by our group30. Previous data also suggested a phenolic linkage point would be
tolerated by VHL and simultaneously permit  incorporation of  the affinity-improving fluorocyclopropyl  amide
group30-32.  By  combining  these  observations  and  utilizing  polyethylene  glycol-based  linkers,  a  small  set  of
PROTACs were designed and subsequently evaluated. Effective PROTACs have been shown to induce stabilizing
protein-protein  interactions  of  the  E3-ligase  with  the  target  protein,  leading  to  cooperative  formation of  a
ternary complex in which the affinity of the PROTAC to both its binding partners is higher than when binding to
each protein individually7, 32, 33. In isothermal titration calorimetry (ITC) assays, binding of PROTAC 1 (2) with the
VHL-ElonginC-ElonginB (VCB) complex displays 4.8 fold greater affinity when already in complex with SMARCA2BD
than it does alone, indicating that ternary complexes formed by this PROTAC are positively cooperative (Fig. 1b
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and 1c, Supplementary Fig. 1a and 1b). We also observed that PROTAC 1 was able to induce partial degradation
of SMARCA2 and SMARCA4 in MV-4-11 cells (Fig. 1d). Interestingly, PROTAC 1 showed a >10 fold weaker binding
affinity  for  the  SMARCA  bromodomain  when  compared  to  the  SMARCABD ligand,  as  measured  by  SPR
(Supplementary  Table  2).  This  drop-off in  binary  affinity,  perhaps due  to an inhibitory  conformation of  the
PROTAC for binding to the ATPase bromodomain, would be classically viewed as a step in the wrong direction.
However,  the cooperative nature, and so enhanced binding affinity of PROTAC 1 at  forming the key ternary
complex species, encouraged us to investigate this compound further. 
To rationalize the cooperative recognition and potentially enable structure-based PROTAC design we solved
a high resolution co-crystal structure of the ternary complex of VCB: PROTAC 1:  SMARCA2BD  (2.25 Å, PDB ID:
6HAY, Fig. 2a, 2b, Supplementary Table 1 and Supplementary Fig. 1c and 2). The crystal structure contains two
copies of the ternary complex in the asymmetric unit, with minor differences between them. The binding mode
of  PROTAC 1 with both  SMARCA2BD and VHL in  the ternary  complex  recapitulates  the key  elements  of  the
respective binary structures for each isolated binder, with a minor rearrangement of the BC loop of SMARCA2BD
when compared to the co-crystal structure of the SMARCABD ligand, to accommodate closer packing against VHL
(Supplementary Fig. 1c). Of particular note, de novo protein-protein interactions were observed in the region of
the BC loop of  SMARCA2BD and the periphery of the VHL binding site (Fig.  2a).  The interface appears to be
stabilized by an electrostatic interaction between R69 of VHL and the carbonyl groups of residues T1462 and
F1463 within the electronegative C-cap of the B helix of SMARCA2BD, as well as a hydrogen bond between Y112
of VHL and N1464 of SMARCA2BD (Fig. 2c). Close packing of these residues around the fluorocyclopropyl amide
group is a key feature of this ternary complex crystal structure. Collapse of the flexible polyethylene glycol-based
linker onto a lipophilic face created in part by Y98 of the VHL protein is also visible in the structure (Fig. 2d). In a
Caco-2 permeability assay, we observed a very low A-B rate of 1.1 x 10 -7 cm/s, a B-A rate of 20.7 x 10 -6 cm/s, and
therefore an efflux permeability ratio of 190 for PROTAC 1, indicating poor passive permeability (A-B) and a high
degree of transporter-mediated efflux (see online methods). Taken together, our data suggest that PROTAC 1
forms moderately cooperative ternary complexes allowing for subsequent degradation and is likely limited by
cellular permeability. 
Structure-based design of a SMARCA2/4 degrading PROTAC
In order to avoid lengthy empirical exploration of structure-activity relationships based on PROTAC 1, we
endeavoured to use the ternary complex co-crystal structure to efficiently guide us towards the design of a more
optimal degrader. Inspection of the ternary complex structure of PROTAC 1 indicates that a large proportion of
the  de novo protein-protein  interactions  exist  around the fluorocyclopropyl  amide moiety  (Fig.  2a  and 2c).
Further, this crystal structure also points towards all other hydrogen bond donor containing functionalities in
PROTAC  1  being  engaged  in  PROTAC-protein  interactions.  We  therefore  decided  to  leave  these  regions
unchanged and optimized the linker interaction with the lipophilic face. To increase conformational restraint, and
attempt to form pi-stacking interactions to Y98, we introduced a benzylic group attached to the piperazine of the
SMARCA-binding motif. Aware that linker geometry could play an important role in defining the ternary complex
arrangement, we used a 1,4-substitution of the newly introduced phenyl ring to mimic the linker conformation
observed for PROTAC 1 in our ternary complex structure and significantly reduce the polarity of the linker. The
resulting compound, PROTAC 2 (3), exhibited a more favourable molecular recognition for the SMARCABD within
the  ternary  complex  (Fig.  3a  and  Supplementary  Table  2).  Furthermore,  an  improvement  in  the  Caco-2
permeability assay was also observed with A-B rate of 8.4 x 10-7 cm/s, a B-A rate of 7.6 x 10-6 cm/s and efflux ratio
of 9.1. The ternary complex co-crystal structure of VCB: PROTAC 2: SMARCA2BD was solved at 2.35 Å resolution
(PDB ID: 6HAX, Fig. 3b-d and Supplementary Table 3). This structure reveals a near identical ternary complex to
that observed with PROTAC 1 with all  de novo protein-protein and protein-PROTAC interactions maintained. As
designed,  the  1,4-substitution  of  the  newly  introduced  phenyl  ring  in  PROTAC  2  indeed  recapitulates  the
geometry of the more flexible linker of PROTAC 1 (Fig. 3c), with the phenyl ring forming an ideal T-stack to Y98 of
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VHL. In addition, the co-crystal structure for VCB: PROTAC 2: SMARCA4BD was also solved (1.76 Å resolution, PDB
ID: 6HR2, Supplementary Fig. 3 and Supplementary Table 3) showing negligible differences in complexes formed
by the bromodomains of either of the two ATPases with PROTAC 2 and VCB. 
A series of competition biophysical assays were also established to further understand the formation of
ternary complexes induced by PROTAC 1 and PROTAC 2. When using PROTAC 1, all assays produced data in good
agreement  with  the  ITC  data  obtained  earlier  for  formation  of  VCB:  PROTAC  1:  SMARCA2BD  complexes
(Supplementary Tables 2 and 4). A fluorescence polarization (FP) assay was developed to measure displacement
of  a  VHL-binding  HIF1α peptide  and  to  determine  the  stability  and  cooperativity  of  ternary  complexes
(Supplementary Table 2 and Supplementary Fig. 4)30, 34. The data show that cooperativity (α) and ternary Ki values
for  VCB:  PROTAC:  BAF  unit  complexes  are  significantly  improved  for  PROTAC 2  as  compared  to  PROTAC 1.
Furthermore, the free energy change of the two-step complex formation process (ΔGcomplex), calculated as a sum
of ΔG values derived from the binary interaction of PROTAC with SMARCA2BD (from SPR KD) and ternary complex
formation of SMARCA2BD: PROTAC complex with VCB (from FP Ki) was found to be 1.4 kcal/mol lower for PROTAC
2 compared with PROTAC 1  (Supplementary Table 5). This shift is equivalent to a ten-fold increase in ternary
complex stability as a result of the structure-based optimization. TR-FRET-based competition assays, measuring
the displacement of a biotinylated SMARCA2 probe (4) in the presence or absence of VCB, were developed as an
orthogonal  approach  to  the  FP  assay.  In  TR-FRET  competition  assays  cooperativity  of  PROTAC 2  is  likewise
improved relative to  PROTAC 1 (Supplementary Table 4,  Supplementary Fig.  5). Using the same biotinylated
SMARCA2 probe, the cooperative nature of both compounds was confirmed in an AlphaLISA assay evaluating
PROTAC induced ternary complexes between full-length proteins within cell lysates (Supplementary Table 6 and‐
Supplementary Fig. 6, see online methods for details).
Emboldened by our crystallographic and biophysical data, we sought to further optimize our degrader by
maintaining the benzylic functionality on the piperazine which had produced improvements in PROTAC 2, while
extending to the same linker  length that had been employed in PROTAC 1,  by introducing an oxygen atom
between the VHL ligand and the phenyl ring of the linker (Fig. 3a). Based on this design rationale, ACBI1 (5) was
prepared and also subjected to evaluation in our FP and TR-FRET biophysical assays (Fig. 3e and f, Supplementary
Tables  2,  4  and  5  and  Supplementary  Fig.  5).  In  both  the  FP  and  TR-FRET  assays,  ACBI1  demonstrated  a
cooperativity (α) of approximately 30. Despite an unimpressive TR-FRET IC50 of 770 nM when measured against
the SMARCA2BD alone, the ternary complex IC50 for ACBI1 in this assay was 26 nM. ACBI1 also demonstrated
significant improvements in the Caco-2 permeability assay with A-B rate of 2.2 x 10-6 cm/s, a B-A rate of 3.8 x 10-6
cm/s and efflux ratio of 1.7. 
The ternary complex crystal structures for PROTAC 1 and PROTAC 2 both suggest a key stabilising role of the
electrostatic  interaction  between  R69  of  VHL  and  the  electronegative  C-terminal  cap  of  the  B  helix  of
SMARCA2BD.  To validate the specificity of the induced PPI in solution a modified VCB complex with an R69A
mutation in VHL (VCBR69A) was utilized. As predicted by the ternary crystallographic data, a significant decrease in
cooperativity is seen for all PROTACs when VCBR69A is used in the TR-FRET assay relative to wild-type (Fig. 3f,
Supplementary Table 4, and Supplementary Fig. 5). Notably, irrespective of the initial cooperativity when using
VCB, for all PROTACS the cooperativity values revert to ~3-4 when using VCBR69A , indicating a limit to the level of
molecular recognition possible when this arginine residue is not present as an anchor point for these complexes.
This data is also highly suggestive that an interaction between R69 of VHL and SMARCA2BD is similarly important
for molecular recognition within the ternary complex formed by ACBI1, as it is for PROTAC 1 and PROTAC 2.
Finally, we evaluated the activity of our PROTACs in cellular assays (Fig. 4a and b and Supplementary Figures
10-11). Complete and potent degradation induced by ACBI1 was observed for SMARCA2 (DC 50 of 6 nM) and
SMARCA4 (DC50 of 11 nM) in MV-4-11 cells, with similar effects on SMARCA2 in SMARCA4-deficient NCI-H1568
cells.  The  SMARCABD ligand  used  in  our  PROTACs  also binds  to  the  5th bromodomain of  the  PBAF  complex
member PBRM1, and ACBI1 is also seen to degrade that protein with a DC50 of 32 nM. As expected, degradation
by PROTAC 2 was sensitive to competition with a VHL inhibitor (6) and was dependent on neddylation35 and
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proteasome activity (Supplementary Fig. 11). Using 1 µM ACBI1, a half maximal degradation occurred well within
2 h for SMARCA2 and SMARCA4 in MV-4-11 cells (Fig. 4a). In line with increased ternary complex stabilities and
expected permeabilities based on evaluation in Caco-2 assays, ACBI1 is a more potent degrader than PROTAC 2,
which in turn is more potent than PROTAC 1.
 To understand the wider effects of our PROTACs on the cellular proteome, unbiased quantitative Tandem
Mass Tag (TMT) labelling and mass spectrometry proteomics was performed with 333 nM of ACBI1 or cis-ACBI1
(7) and a treatment time of 8 h in MV-4-11 cells (Fig.  4c).  The data corroborate a significant knockdown of
SMARCA2,  SMARCA4 and PBRM1 with  minimal  down-regulation of  other  proteins  across  the proteome.  To
further understand the  effects of chemically induced ATPase degradation on BAF/PBAF complex integrity, we
immunoprecipitated complexes from cell extracts  using antibodies against the SMARCC2/BAF170 and ARID1A
subunits and identified specifically enriched associating proteins by mass spectrometry. Treatment with PROTAC
2 led, as expected, to a less efficient recovery of SMARCA2, SMARCA4 and PBRM1 (Fig. 4d and Supplementary
Fig.  12  and  13).  The  majority  of  accessory  subunits  remain  associated,  but  it  is  clear  that  some  core
subunits such as ACTL6A, the BAF specific BCL proteins and the PBAF specific PHF10 protein are co-depleted. The
TMT proteomics data with both PROTAC 2 and ACBI1 show no reduction in ACTL6A suggesting dissociation of this
subunit from the complex following ATPase degradation (Fig. 4c and Supplementary Fig. 12a). 
Degradation of SMARCA2/4 causes cancer cell death 
The ATPases of the BAF complex have been shown to be essential in certain cancer cell lines. SMARCA4
supports AML cell proliferation by maintaining an essential enhancer17, whereas in several solid cancer types,
mutational loss of SMARCA4 leads to a dependence on active SMARCA218-20, 24. We therefore tested the effects of
PROTAC-mediated loss of SMARCA2 and SMARCA4 on proliferation of a panel of cancer cell lines (Fig. 5a and
Supplementary Fig. 14) . We first tested the activity of ACBI1 on cells known to depend on an intact BAF complex:
leukemia cell lines, such as MV-4-11, as well as the SMARCA4-deficient cells SK-MEL-5 and NCI-H1568. In all cell
lines tested, ACBI1 exerted potent anti-proliferative effects. In MV-4-11 and SK-MEL-5 cells, its non-degrading
distomer cis-ACBI1 remained inactive. ACBI1 demonstrated an anti-proliferative IC50 of 28 nM in MV-4-11 cells,
broadly in line with its DC50 of 6 nM. The SMARCABD ligand, i.e. the bromodomain binder without the linker and
VHL-binding part, had no antiproliferative effect in any cell line. Surprisingly, an antiproliferative effect was seen
with cis-ACBI1 in NCI-H1568 cells, albeit at significantly higher concentration than ACBI1 (IC50 of 441 nM vs. 68
nM, Supplementary Fig. 14b). The reasons for this effect are presently unclear. A series of studies were next
carried out to demonstrate that the effects of the PROTACs were due to on-target degradation of SMARCA2 and
SMARCA4. Firstly, we combined high amounts of the SMARCABD ligand with titrations of ACBI1 to compete for
bromodomain  binding.  As  expected,  competing  amounts  of  SMARCABD ligand reduced  ACBI1-induced
degradation of SMARCA2 as well as the negative effects on cell proliferation (Fig.5b and Supplementary Fig. 14c
and d). Secondly,  a lung adenocarcinoma cell line deficient in both SMARCA2 and SMARCA4, NCI-H1703, was
chosen to assess  potential  off-target  activity  of  ACBI1.  Both ACBI1  and  cis-ACBI1  show no anti-proliferative
effects  in  this  SMARCA2/4  null  cell  line  (Fig.  5a).  These  cells  remain  competent  to  degrade  BAF  complex
members, as ectopically expressed SMARCA2 was efficiently eliminated in the presence of PROTAC 2, but not the
non-VHL-binding version of this,  cis-PROTAC 2 (8) (Supplementary Fig. 15a). SMARCA2 bearing an inactivating
mutation (see online  methods)  in  the bromodomain (SMARCA2 bromodead)  was stable  in  the presence of
PROTAC  2,  confirming  that  degradation  depends  on  the  compound  interacting  with  an  intact  SMARCA2
bromodomain (Supplementary Fig. 15a). In NCI-H1568 cells over-expressing PBRM1, ACBI1 showed similar anti-
proliferative effect  in  comparison to a vector  control,  whereas the overexpression of  SMARCA2 produced a
significant rightward shift in anti-proliferative IC50 as well as attenuating maximal effect (Supplementary Fig. 15b-
d). Taking into consideration that ACBI does not induce degradation of proteins other than SMARCA2, SMARCA4
and PBRM1, this supports insufficient amounts of SMARCA2 following ACBI1 treatment being the driver of the
observed phenotype. 
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We then assessed the extent of cellular apoptosis induced by compound treatment. ACBI1-mediated loss of
SMARCA2 led to increased caspase activity in SK-MEL-5, comparable to that seen with the chemotherapeutic
drug doxorubicin (Fig. 5c). In SK-MEL-5 cells, the fraction of caspase-positive cells steeply increased after 40 h of
treatment  alongside  the  appearance  of  cleaved  PARP ,  confirming  the  induction  of  apoptosis  in  these  cells
(Supplementary Fig. 15e).  These results confirm that the vulnerability of cancer cells to SMARCA subunit loss
demonstrated by genetic means can be recapitulated upon chemically induced degradation. 
Discussion
In  this  study  we  describe  how  structure-based  design  guided  us  to  improve  the  characteristics  of  a
bifunctional degrader molecule. We showed that despite binding to the protein target of interest with weaker
affinity than the analogous  SMARCABD ligand,  a  prototype compound PROTAC 1 formed cooperative ternary
complexes  and  was  active  as  a  degrader,  and  thus  a  promising  lead  for  PROTAC  optimization.  Co-crystal
structures  identified  the  key  induced  interactions  that  were  central  to  stabilize  the  ternary  complex  and
delineated  the  conformation  and  interactions  of  the  polyethylene  glycol  linker.  This  information  saved
considerable time and effort by guiding us away from changing regions of the PROTAC structure that could have
been inhibitory to complex formation, a likely path if following an empirical approach. Rather, this data informed
the introduction of a disubstituted phenyl ring to enhance conformational restraint  and form novel protein-linker
interactions, while simultaneously  reducing polarity  of  the molecule in a targeted way to give PROTAC 2.  A
subsequent ternary co-crystal structure and allied biophysical studies with PROTAC 2 showed improvements in
molecular recognition and free energy of ternary complex formation for this compound, validating the design
hypotheses. In a further round of design the linker length was extended to that used in PROTAC 1 while retaining
the benzyl  moiety  on the piperazine ring  to  yield  ACBI1.  These three PROTACs showed progressively  more
cooperative behavior in FP and TR-FRET ternary complex assays. In line with this and with improvements in
permeability, these PROTACs induced degradation of their targets with increasing potency in cells. Our findings
together qualify ACBI1 as a potent degrader of BAF complex ATPases in multiple cancer cell lines, and furnish a
first-in-class chemical tool for acute and profound SMARCA2/4 knockdown.
We exemplify the efficiency of structure-based PROTAC design and further demonstrate how non-functional
domains  can  provide  suitable  handles  for  targeted  degradation10.  Prioritizing  and  designing  bifunctional
molecules on the basis of their ability to induce stable complexes between the E3 ligase and the target is broadly
applicable and may greatly reduce the empirical nature of PROTAC design that has dominated to date. Whilst
cooperativity of ternary complexes is not essential for PROTAC-induced protein degradation8, 33, 36, we show that
the  identification  of  compounds  that  induce  stable  complexes  can  provide  rational  starting  points  for
optimization, even if those molecules are suboptimal at inducing protein degradation or retaining the binary
binding affinity of the constitutive target/ligase-binding units.
Unbiased  whole  cell  proteomic  analysis  confirmed  exquisitely  selective  ACBI1-mediated  target  protein
knockdown and IP-MS experiments with its analogue PROTAC 2, showed that the majority of  BAF/PBAF subunits
remain associated following PROTAC treatment. Several BAF subunits including ACTB, ACTL6A, BCL7A and PHF10
were consistently co-depleted from immunopurified complexes with SMARCA2, SMARCA4 and PBRM1. Many of
these proteins are known to interact with SMARCA2, SMARCA4 and PBRM1  and are likely to dissociate as a result
of loss of contact with these subunits, supported by our data showing total protein levels of ACTL6A are not
changed20, 37, 38.  At the outset of our study, it was not known if degradation of individual subunits out of stable
BAF/PBAF  multi-protein  complexes  by  PROTACs  was  possible.  By  addressing  this we  have  demonstrated
the potential for acute chemically mediated manipulation of BAF/PBAF composition, which is of value both in the
design of future therapeutics and as research tools.
 The dependence of certain cancer types on the BAF complex paralog ATPases SMARCA2 and SMARCA4 has
been  unequivocally  shown  both  by  RNA  interference  and  CRISPR-based  knockouts18-20,  24,  39,  40.  However,
chemically-induced knockdown targeting these BAF complex subunits has not been demonstrated so far. Our
work shows that targeting the SMARCA2/4 bromodomains for protein degradation can exploit these identified
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cancer vulnerabilities and phenocopies the genetic knockdowns. The nature of the anti-proliferative effect of loss
of  BAF  complex  members  has  not  been  comprehensively  investigated20.  We  show  here  that  SMARCA2/4-
degrading PROTACs can induce rapid apoptosis in a subset of SMARCA4-deficient cells. Additional studies are
required to understand the differential rate in responses of a subset of cancer cells that have adapted to loss of
SMARCA4 (e.g. NCI-H1568 vs. SK-MEL-5). Using our dual SMARCA2/4-degrading PROTACs, we were also able to
show anti-proliferative effects in AML cells,  consistent with earlier knockdown studies showing sensitivity of
these  cells  to  SMARCA4 depletion17. While  mice  lacking  functional  SMARCA2 develop  normally,  the loss  of
SMARCA4  results  in  embryonic  death  in  mice39-42.  Therefore,  whilst  it  is  likely  that  a  selective  degrader  of
SMARCA2 will not have dramatic on-target side effects, it remains to be seen whether SMARCA4 degradation can
be therapeutically translated. In addition to targeting the BAF complex ATPases, ACBI1 also causes degradation of
PBRM1 albeit with lower potency. However, overexpression of PBRM1 in NCI-H1568 cells failed to rescue the
effects of ACBI1 on cell growth whereas SMARCA2 overexpression indeed attenuated the effect, suggesting that
that loss of PBRM1 alone does not exert the anti-proliferative effects observed.  Future studies are warranted
toward deeper mechanistic understanding of the downstream effects of degrading BAF ATPase subunits in both
cancerous and non-cancerous cells.  We anticipate that progress in this direction will  be greatly advanced by
sharing the chemical tools that have emerged from our work with the wider community. Finally, we hope that
structure-based design becomes a central approach in the emerging PROTAC field as it has in more traditional
areas of drug discovery.
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Figure Legends
Figure 1. Rational design and evaluation of a partial degrader of SMARCA2 and SMARCA4, PROTAC 1 a) 2D chemical structure of a 
SMARCABD ligand and crystal structure of this ligand in complex with SMARCA2BD. The piperazine ring was selected as an exit vector for 
PROTAC linkage as it is directed into solvent away from the binding site. b) 2D chemical structure of PROTAC 1 c) Inverse ITC titrations of 
VCB into PROTAC 1 (left) and VCB into the preformed PROTAC 1–SMARCA2BD complex (right), n = 2. PROTAC 1 binds VCB with higher 
affinity when in complex with SMARCA2BD and is therefore cooperative, α = 4.8.  d) Degradation of SMARCA2 and SMARCA4 in MV-4-11 
cells following treatment with PROTAC 1, analysed via capillary electrophoresis (see online methods). For SMARCA2 and SMARCA4, 
maximal degradation is ~65 % and ~70%, and DC50 is 300 nM and 250 nM, respectively. Data represent means from two biologically 
independent experiments, ± S.E.M.
Figure 2. Ternary co-crystal structure of SMARCA2BD: PROTAC 1: VCB. a) Overall co-crystal structure of VCB: PROTAC 1: SMARCA2BD in 
ribbon representation with bound PROTAC shown in stick with magenta carbons. b) Fo-Fc omit map (green meshes) of PROTAC 1 prior to 
ligand modelling (complex 1, interface of chains A/B) contoured at 3.0 σ with a carve radius of 2.2 Å. c) Key electrostatic protein-protein 
interactions between R69 of VHL and C-terminal backbone carbonyl groups of the B helix of SMARCA2BD d) Surface representation colored
using normalized consensus hydrophobicity scale, red = hydrophobic, white = hydrophilic. Linker of PROTAC 1 seen to be collapsing on to a
lipophilic face formed in part by Y98 of VHL.
Figure 3. Ternary co-crystal structure of SMARCA2BD: PROTAC 2: VCB and biophysical data validate a rational design strategy a) 2D 
chemical structures of PROTAC 2 and ACBI1 b) Overlays of ternary crystal structures of VCB: PROTAC 1 : SMARCA2BD (orange, PROTAC 
carbons in magenta) and VCB: PROTAC 2 : SMARCA2BD (2.35 Å, salmon, PROTAC carbons in green). Near identical ternary complexes are 
formed by both PROTACs; with the phenyl ring of PROTAC 2 in close proximity to Y98 of VHL. c) Overlays show that the constrained 1,4-
disubstituted phenyl ring of PROTAC 2 (green carbons) accurately recapitulates the linker geometry observed previously for PROTAC 1 
(magenta carbons). d) Fo-Fc omit map (green meshes) of PROTAC 2 prior to ligand modelling contoured at 3.0 σ with a carve radius of 2.2 
Å. e) Fitted curves from Fluorescence Polarization competition assays measuring displacement of a VHL peptide by PROTACs in the 
presence or absence of SMARCA2BD. ACBI1 forms more cooperative and stable complexes compared with PROTAC 1. Curves are a best fit 
of means from n = 3 biologically independent experiments, ± S.E.M. f) Fitted curves for TR-FRET assays measuring displacement of a 
biotinylated SMARCA2BD probe by PROTAC alone, in complex with VCB or in complex with an R69A variant of VCB. A significant rightward 
shift when using VCBR69A vs VCB highlights the importance of this residue in ternary complex formation in solution. Curves are a best fit 
of means from n = 3 biologically independent experiments, ± S.D.
Figure 4. ACBI1 is a potent and selective degrader of SMARCA2, SMARCA4 and PBRM1. a) Degradation of endogenous SMARCA2, 
SMARCA4 and PBRM1 in MV-4-11 cells treated for 18 h gave a DC50 of 6, 11 and 32 nM respectively (left). Time course of degradation in 
MV-4-11 in the presence of 1 µM of ACBI1 or 1 µM cis-ACBI1 (right). Two independent experiments. b) Degradation of endogenous 
SMARCA2 in NCI-H1568 cells treated for 18 h gave a DC50 of 3.3nM for SMARCA2 and 15.6 nM for PBRM1 Two independent experiments. 
c) Effects of ACBI1 (blue) and cis-ACBI1 (red) at 333 nM for 8 h on the proteome of MV-4-11 cells. Data plotted Log2 of the fold change 
versus DMSO control against –Log10 of the p value per protein from n = 3 independent experiments. All t-tests performed were two-tailed 
t-tests assuming equal variances d) SWI/SNF complexes were immuno-purified from MV-4-11 cell lysates following PROTAC treatment and
abundance of subunits was determined by label free quantitation. Data plotted as fold change in abundance for PROTAC 2 vs cis-PROTAC 2
treatment against –Log10 of the p value per protein from n = 3 biologically independent experiments. Subunits of the SWI/SNF complex are
highlighted. All t-tests performed were two-tailed t-tests assuming equal variances.
Figure 5. Effects on the proliferation and apoptosis of cancer cells in the presence of ACBI1. a) Cell viability of an AML cell line, MV-4-11 
(left), a SMARCA4 deficient melanoma cell line, SK-MEL-5 (centre) and a SMARCA2 and SMARCA4 deficient NSCLC cell line, NCI-H1703 
(right), after 7 days in the presence of ACB.I1. IC50s for ACBI1 and cis-ACBI1 in MV-4-11 cells are 29 nM and 1.4 µM, and in SK-MEL-5 cells 
are 77 nM and > 10000 nM, respectively. Two independent experiments. b) Cell viability of a melanoma cell line, SK-MEL-5 after 3 days in 
the presence of dose titrations of ACBI1, the SMARCABD ligand or a dose titration of ACBI1 in the presence of 10 µM of SMARCABD ligand, 
representative of two biologically independent experiments. c) Real-time measurement of proliferation (left) and apoptosis (right) in SK-
MEL-5 cells after treatment with doxorubicin (1 µM), ACBI1 (0.3 µM) and cis-ACBI1 (0.3 µM). Representative of two biologically 
independent experiments. 
ONLINE METHODS
Chemical  synthesis.  Synthesis  of  compounds  described  in  this  paper  and  their  intermediates  are  described  in  the
Supplementary Note.
Cell lines and culture
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Cell  lines  were  obtained  through  ATCC,  verified  for  identity  by  satellite  repeat  analysis  and  tested  for  mycoplasma
contamination. Cells  were grown in the medium as specified by the supplier unless described otherwise and not used
beyond passage 25.
Caco-2 permeability assay
Caco-2 cells (1-2 × 105 cells/1 cm2) were seeded on filter inserts (Costar transwell polycarbonate or PET filters, 0.4 µm pore)
and cultured in DMEM for 10 to 25 days. Compounds were dissolved in appropriate solvent (1-20 mM stock solutions were
diluted with HTP-4 buffer  (128.13 mM NaCl,  5.36 mM KCl,  1  mM MgSO4,  1.8 mM CaCl2,  4.17 mM NaHCO3,  1.19 mM
Na2HPO4.7H2O,  0.41 mM NaH2PO4.H2O,  15 mM HEPES,  20  mM glucose,  pH 7.2)  containing  0.25% BSA to  prepare the
transport solutions (0.1 - 300 µM compound, final dimethyl sulfoxide (DMSO) concentration ≤0.5%). Transport solution (TL)
was applied to the apical or basolateral donor side for measuring A-B or B-A permeability (3 filter replicates), respectively.
The receiver side contained HTP-4 buffer supplemented with 0.25% BSA. Samples were collected at the start and end of
experiment  from the donor  and at  various time intervals  for  up to  2  h also  from the receiver  side  for  concentration
measurement by HPLC-MS/MS. Sampled receiver volumes were replaced with fresh receiver solution.
Constructs, protein expression and purification of VCB and SMARCA2, SMARCA4 and PBRM1 bromodomains 
Wild-type and mutant versions of human proteins were used for all protein expression, as follows: VHL (UniProt accession
number: P40337), ElonginC (Q15369), ElonginB (Q15370) and the bromodomains (BDs) of SMARCA2 (SMARCA2 BD; P51531-
2, residues 1373-1493 with additional N-terminal SM residues (cloning artefact)), SMARCA4 (SMARCA4BD; P51532, residues
1448-1569  with additional N-terminal SM residues (cloning artifact)),  and the fifth bromodomain of PBRM1 (PBRM1BD5,
Q86U86,  residues  645-766).  SMARCA4BD was  provided  by  the  Structural  Genomics  Consortium  (SGC),  Toronto43 and
SMARCA2BD and PRM1BD5 were synthesised by GeneArt then subcloned into pDEST15 vectors (Invitrogen). The VCB complex
was expressed and purified as described previously, with the modification that 0.3 mM IPTG was used for induction of
expression7. Briefly, N-terminally His6-tagged VHL (54-213), ElonginC (17-112) and ElonginB (1-104) were co-expressed and
the complex isolated by Ni-affinity chromatography, the His6 tag was removed using TEV protease, and the complex further
purified by anion exchange and size-exclusion chromatography (SEC). The VCBR69A mutant, in which R69 of VHL (54-213) was
mutated  to  alanine,  was  generated  using  a  QuickChange  II  site-directed  mutagenesis  kit  (Agilent)  according  to  the
manufacturer’s  instructions  and  expressed  and  purified  as  for  VBC.  Both  were  stored  in  20  mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 150 mM sodium chloride and 1 mM tris(2-carboxyethyl)phosphine (TCEP) pH 7.5.
SMARCA2BD, SMARCA4BD and PBRM1BD5 were expressed in Escherichia coli BL21(DE3) as N-terminal GST-fusion proteins with
a TEV protease cleavage site.  Expression and purification of  these proteins  has  been described previously 43,  44.  Starter
cultures were grown overnight at 37 °C in 10 mL of Luria-Bertani (LB) medium with ampicillin (100  g/mL). The starter
cultures were diluted (1:100) in Terrific Broth (TB) medium with ampicillin (100 g/mL) and grown in a shaking incubator at
37 °C to an optical density (OD600) ~ 1 before the temperature was lowered for induction (to 23 °C for SMARCA2BD or 18 °C
for SMARCA4BD and PRRM1BD5). Expression was induced using IPTG (final concentration 0.3 mM for SMARCA2BD, PBRM1BD5,
0.4 mM for SMARCA4BD) for 16 h at the specified temperatures. Cells were harvested by centrifugation and stored at -80 °C
prior to purification. Cells were resuspended in Lysis buffer and lysed by sonication (20 pulses of 5 s for 4 min) using a
Sonopuls HD 3080 (Bandelin, Berlin, Germany) or by homogenization using a Stansted Pressure Cell Homogenizer (Stansted
Fluid Power). The Lysis buffers were as follows: for SMARCA2BD: 50 mM HEPES, 500 mM sodium chloride, 5% glycerol, 5 mM
dithiothreitol (DTT); for SMARCA4BD: 25 mM HEPES, 0.3 M sodium chloride, 5% glycerol, 10 mM DTT, pH 7.5; for PBRM1 BD5:
25 mM HEPES,  300 mM sodium chloride,  5% glycerol,  10 mM DTT, pH 7.8;  in  each case supplemented with complete
protease inhibitors (Roche). Affinity purification was performed using Glutathione Sepharose 4B (GE Healthcare) in batch
mode or on-column. Cleavage of the GST-tag was performed using TEV protease for 16 h at 4 °C, either on -column, or in
solution following elution of the GST-tagged BDs with Lysis buffer containing 20 mM reduced L-glutathione (Sigma Aldrich).
For SMARCA2BD, prior to TEV protease cleavage the eluted GST-tagged BD was first dialysed into desalting buffer (20 mM
HEPES, 250 mM sodium chloride, pH 7.0 + 0.5% glycerol). Where TEV cleavage was performed in solution, a second affinity
(GST-trap) column purification step was carried out to remove the GST-tag and uncleaved GST-tagged protein. Proteins were
further purified by SEC (HiLoad Superdex-75, 16/600) (GE Healthcare) and stored in Storage buffer (for SMARCA2 BD: 20 mM
HEPES, 150 mM sodium chloride, pH 7.5; for SMARCA4BD: 10 mM HEPES, 0.5 M NaCl, 5% glycerol, pH 7.5; for PBRM1BD5: 20
mM HEPES, 300 mM NaCl, 5 mM DTT, pH 7.8). For AlphaScreen assays, eluted GST-tagged BDs were purified directly by SEC
in the respective storage buffers without TEV cleavage. All chromatography purification steps were performed either at
room temperature or 4 °C using an ÄKTA FPLC purification system (GE Healthcare) or a plastic Econo-Pac column (Bio-Rad).
Isothermal titration calorimetry (ITC)
Titrations for cooperativity experiments were performed at 25 °C on a MicroCal  PEAQ-ITC or ITC200 micro -calorimeter
(Malvern) in reverse mode (protein in syringe, ligand in cell) as described previously7. Briefly, PROTACs (ACBI1 or ACBI2)
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were  diluted  from  a  10 mM  DMSO  stock  solution  to  20  μM  in  buffer  consisting  of  20  mM  1,3-
bis[tris(hydroxymethyl)methylamino]propane  (BIS-TRIS)  propane,  150 mM  NaCl,  1 mM  TCEP,  pH  7.4  and  a  final  DMSO
concentration of 0.2%. Two sets of sequential titrations were performed; firstly, a titration of SMARCA2 BD (200 μM, in the
syringe) into the PROTAC solution (20 μM, in the cell),  followed by a titration of VCB complex solution (168 μM in the
syringe) into the PROTAC–SMARCA2BD complex solution retained in the cell. Binary experiments consisted of an analogous
initial single injection of buffer (syringe) into the PROTAC solution (20 μM, in the cell), followed by a titration of VCB complex
solution (168 μM in the syringe) into the diluted PROTAC solution retained in the cell. Data were fitted to a single-binding-
site model to obtain the stoichiometry (n), the dissociation constant (KD) and the enthalpy of binding (ΔH) using MicroCal
PEAQ-ITC Analysis Software (Malvern). Cooperativity values were calculated as the ratio of  KD values determined for VCB
binding to a PROTAC or to a PROTAC–SMARCA2BD complex (i.e. binary KD/ternary KD). The reported values are the mean ±
S.D. from two independent measurements.
FP competition assays
To evaluate  cooperativity  of  PROTAC binding to  VCB in  the  absence  or  presence  of  saturating concentrations of  each
bromodomain,  an  existing  fluorescence  polarisation  assay  in  competition  format  was  utilized,  with  only  minor
modifications30, 34. Fluorescence polarisation experiments were performed at room temperature on a PHERAstar FS (BMG
LABTECH) in 384-well plates (Corning 3820), with excitation at 485 nm and emission at 520 nm. The fluorescent peptide
employed  in  these  experiments  was  a  5,6-Carboxyfluorescein  (FAM)-labelled  HIF-1α  peptide  (FAM-
DEALAHyp-YIPMDDDFQLRSF, measured KD for VCB ~ 1-2 nM) (‘JC9’). The assay buffer was 100 mM BIS-TRIS, 100 mM NaCl, 1
mM DTT, pH 7, supplemented with compound/DMSO vehicle (final DMSO concentration 1%). The final assay volume per
well was 15 µL. A direct titration of VCB against the fluorescent peptide was firstly performed using 5 nM of peptide and
decreasing  concentrations  of  VCB  (15-point  two-fold  serial  dilution  from  100  µM  to  6.1  nM,  triplicate  wells).  Next  a
competition experiment was performed using each PROTAC (14-point half-log-fold serial dilution from 50 µM to 0.016 nM)
in the absence or presence of a saturating concentration of SMARCA2BD, SMARCA4BD or PBRM1BD5 (75 µM for SMARCA2BD
150  µM  for  SMARCA4BD and  100  µM  for  PBRM1BD5).  The concentration  of  bromodomain  was  calculated  such  that  it
remained in molar excess relative to PROTAC, with the lowest concentration selected being greater than 10-fold the weakest
PROTAC KD for that particular bromodomain (>90% fractional occupancy). For each independent experiment, titrations were
performed using duplicate wells. IC50  values were calculated in Prism (Version 7.03, GraphPad). Curves were fitted using
nonlinear regression (four-parameter fit) following normalisation to percentage of maximum signal based on corresponding
DMSO controls for each treatment type. KD values were back-calculated from fitted IC50 values as described previously30, 34.
Cooperativity values (α) for each PROTAC were calculated using the ratio:
α = KD(-bromodomain) / KD(+bromodomain)
The reported values are the mean ± S.E.M. from 3 independent measurements (duplicate wells).
TR-FRET competition assays
To evaluate cooperativity of PROTAC binding to SMARCA2BD, a TR-FRET assay was developed in a competition format using a
biotinylated SMARCA2 probe (4)28 (KD for SMARCA2BD ~ 400 nM) and His6-tagged SMARCA2BD. PROTAC binding to SMARCA2BD
was then measured in the absence or presence of saturating concentrations of VCB.
All assays were performed at room temperature in a Proxiplate-384 PLUS, white (PerkinElmer) plate. Reagents were diluted
in buffer, consisting of 50 mM HEPES, 50 mM sodium chloride, 2 mM DTT, 0.008% Brij, 0.01% BSA at pH 7.3, and were
allowed to equilibrate to room temperature prior to addition to plates. The final concentrations in the assay were as follows:
40 nM SMARCA2BD, a concentration series of each PROTAC (10 µM to 1 nM, 11-point half-log-fold serial dilution), 16.6 nM
biotinylated probe  5,  2.5 nM Lance Eu-W1024 labeled Streptavidin (Perkin Elmer Cat No AD0062, 50 µg, 500 µg/mL, 8.3
µM ), 50nM ULight-anti His6 AB (Perkin Elmer TRF0105-M, 5 µM, 800 µg/mL) and either assay buffer or 5 µM VCB at a final
DMSO concentration of 1%. SMARCA2BD, Streptavidin-Eu and U-Light AB were mixed in assay buffer (SMARCA2 solution) and
kept at room temperature prior to use. 5 nL of the biotinylated probe solution was added to rows 1-23 (with the Labcyte
Echo 55x) and 187.5 nL VCB (or assay buffer) was transferred with the Labcyte Echo 55x to rows 1-23. 15 µL of the SMARCA2
solution was subsequently added to rows 1-24. Plates were incubated at room temperature for 60 minutes and the signal
was measured in a PerkinElmer Envision HTS Multilabel Reader using the TR-FRET LANCE Ultra specs from PerkinElmer (665
nm/615 nm × 10000). 
Each plate contained 16 wells of a negative control (diluted DMSO instead of test compound with biotinylated probe) and 16
wells  of  a  positive  control  (diluted  DMSO instead  of  test  compound  without  biotinylated  probe).  The  average  of  the
background control (positive control, without enzyme) was calculated and subtracted from the measured values for each
plate. IC50 values were calculated and analyzed using a 4 parametric logistic model for each PROTAC in the absence or
presence of saturating concentrations of VCB. Cooperativity values (α) for each PROTAC were calculated using the ratio:
α = IC50(-VCB) / IC50(+VCB)
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Note; ‘VCB’ represents either VCB or VCBR69A. The reported values are the mean ± S.E.M. from 3 independent measurements
(duplicate wells).
SMARCA2: (1) crystallography
The  binary  crystal  complex  structure  of  SMARCA2BD:  (1)  was  obtained  by  ligand  soaking  into  crystals  of  SMARCA2BD.
Crystallisation  of  SMARCA2BD (14 mg/mL  in  25  mM  tris(hydroxymethyl)aminomethane  (TRIS)  pH  8,  150  mM  sodium
chloride) was carried out at 4 °C using the sitting-drop method (0.2 L of each of protein/reservoir solutions, using a small
seed stock of  disrupted crystals  added to  the protein  immediately  prior  to drop setting).  Crystals  were obtained after
approximately 14-21 days in reservoir solution consisting of 25% (w/v) PEG 6000, 0.1 M HEPES pH 6.1, 0.01 M zinc chloride,
0.01 M cobalt (III) hexamine chloride, 8% (v/v) ethylene glycol. For ligand soaking experiments, 1 L of a 10 mM DMSO stock
solution of (1) was dried and re-dissolved in 1 L of reservoir solution, into which crystals of SMARCA2BD were soaked for 5
days, then flash cooled in liquid nitrogen using reservoir solution containing 25% ethylene glycol as a cryo -protectant. Data
were collected at the SLS beam line PXII  (Swiss Light Source, Paul Scherrer Institute, λ = 1.000 Å) using a PILATUS 6M
detector. The crystals belonged to space group P 41 with unit cell parameters a = 42.5, b = 42.5, c = 164.2 Å and α, β, γ = 90°
and  contained  two monomers  per  asymmetric  unit.  Images  were  processed  with  autoPROC  incorporating  STARANISO
(Tickle, I.J., Flensburg, C., Keller, P., Paciorek, W., Sharff, A., Vonrhein, C., Bricogne, G. (2018). STARANISO. Cambridge, United
Kingdom: Global Phasing Ltd.)45. The resolution limit was set to 1.33 Å using local(I/σI) ≥ 1.20. The structure was solved by
molecular replacement using a SMARCA2BD crystal structure (PDB entry 4QY4; https://www.thesgc.org/structures/4qy4) as a
search model. Subsequent iterative model building and refinement was done according to standard protocols using CCP4 46,
COOT47 and autoBUSTER (Global  Phasing Ltd.).  The structure was refined to  Rwork and  Rfree values of  17.9% and 19.3%,
respectively, with 100% of the residues in Ramachandran favoured regions as validated with MOLPROBITY48.
Ligand restraint and initial coordinate files for all structures were generated using GRADE (O. S. Smart, T. O. Womack, A.
Sharff, C. Flensburg, P. Keller, W. Paciorek, C. Vonrhein, and G. Bricogne. (2011) grade, version 1.2.13. Cambridge, United
Kingdom, Global Phasing Ltd.,  http://www.globalphasing.com) incorporating crystallographic geometry information from
MOGUL49. Data collection and refinement statistics for all structures are described in Supplementary Table 1.
VCB: (2):SMARCA2BD ternary complex crystallography
VCB, (2) and SMARCA2BD were mixed in a 1:1:1 stoichiometric ratio in 20 mM HEPES, pH 7.5, 150 mM sodium chloride, 1
mM  TCEP,  2%  DMSO,  incubated  for  5  minutes  at  room  temperature  and  concentrated  to  a  final  concentration  of
approximately  8 mg/mL. Drops were prepared by mixing 1  L of  the ternary complex with  1  L of  well  solution and
crystallised at 4°C using the hanging-drop vapour diffusion method. Crystals were obtained in 18% (w/v) PEG 3350, 0.2 M
sodium formate, 0.1 M HEPES, pH 7.75, and formed within 24 h but were fully grown after a few days. Harvested crystals
were flash cooled in liquid nitrogen following gradual equilibration into cryo-protectant solution consisting of 25% (v/v)
ethylene glycol in 19% PEG 3350, 0.2 M sodium formate, 0.1 M HEPES, pH 7.75. Diffraction data were collected at Diamond
Light Source beamline I04-1 (λ = 0.91587 Å) using a Pilatus 6M-F detector and processed using XDS50. The crystals belonged
to space group P 21 21 21 with unit cell parameters a = 79.7, b = 117.3, c = 121.6 Å and α, β, γ = 90° and contained two copies
of the ternary complex per asymmetric unit. The structure was solved by molecular replacement using PHASER with VCB
coordinates derived from the VCB:MZ1:Brd4BD2 complex (PDB entry 5T35) and SMARCA2BD (PDB entry 4QY4)51 as search
models.  Subsequent  iterative  model  building  and  refinement  was  done  according  to  standard  protocols  using  CCP4 46,
COOT47 and autoBUSTER (Global  Phasing Ltd.).  The structure was refined to  Rwork and  Rfree values of  19.3% and 22.4%,
respectively, with 97.9% of the residues in Ramachandran favoured regions as validated with MOLPROBITY48.
VCB:(3):SMARCA2BD ternary complex crystallography
The ternary complex of VCB: (3):SMARCA2BD  (at approximately 14 mg/mL) was prepared and crystallised as for the VCB:
(2):SMARCA2BD complex,  in well  solution comprising 13% (w/v) PEG 3350, 0.2 M sodium formate, 0.1 M HEPES, pH 8.0.
Harvested  crystals  were  flash  cooled  in  liquid  nitrogen  following  gradual  equilibration  into  cryo-protectant  solution
consisting of 25% (v/v) ethylene glycol in 20% PEG 3350, 0.2 M sodium formate, 0.1 M HEPES, pH 8.0. Diffraction data were
collected at Diamond Light Source beamline I24 (λ = 0.97998 Å) using a Pilatus3 6M detector and processed using XDS 50. The
crystals belonged to space group P 21 21 21 with unit cell parameters a = 80.5, b = 116.2, c = 120.6 Å and α, β, γ = 90° and
contained two copies of the ternary complex per asymmetric unit. The structure was solved by molecular replacement and
built, refined and the geometry validated as for the VCB: (2):SMARCA2BD ternary complex, to final  Rwork and Rfree values of
23.2%  and  26.8%,  respectively,  with  97.6%  of  the  residues  in  Ramachandran  favoured  regions  as  validated  with
MOLPROBITY48.
VCB:(3):SMARCA4BD ternary complex crystallography
The ternary complex of VCB:ACBI1:SMARCA4BD (at approximately 14 mg/mL) was prepared and crystallised in well solution
comprising 20% (w/v) PEG 1500, 0.1 M MIB buffer, pH 6.0. Harvested crystals were flash cooled in liquid nitrogen following
gradual equilibration into cryo-protectant solution consisting of 25% (v/v) ethylene glycol in 25% PEG 1500,  0.1 M MES, pH
6.0. Diffraction data were collected at SLS beamline X10SA (λ = 1.000 Å) using a Pilatus3 6M detector and processed using
AUTOPROC. The crystals belonged to space group P 1 with unit cell parameters a = 66.33, b = 61.68, c = 81.63 Å and α =
13
69.43, β =83.38, γ = 86.42° and contained two copies of the ternary complex per asymmetric unit. The structure was solved
by molecular replacement and built, refined and the geometry validated as for the VCB: (2):SMARCA2BD ternary complex, to
final Rwork and Rfree values of 21.6% and 23.6%, respectively, with 97.4 % of the residues in Ramachandran favoured regions as
validated with MOLPROBITY9.
Transfection, lysis and protein detection for AlphaLISA assays
HEK293 cells in DMEM (Invitrogen) were seeded at 3-3.5 × 105 cells/well of 6 well plates and the medium was replaced on
the day of transfection.  The pIRESpuro3 vector (Clontech)  containing an insert  for C-terminal  3×FLAG-tagged wild-type
SMARCA2 (Uniprot  identifier:  P51531-1)  or  SMARCA4 (P51532-1)  were  transiently  transfected  into  HEK293  cells  using
lipofectamine 2000 (Invitrogen) and OptiMEM (Invitrogen). Untransfected cells and cells transfected with the empty vector
were used as negative controls. After 48 h, cells were washed twice in cold PBS (Invitrogen) and lysed in hypotonic buffer
containing 10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 50 units/mL benzonase nuclease (Sigma) and protease inhibitor
cocktail (Roche) by Dounce homogenisation. Protein samples were cleared by centrifugation at 4 °C, at 1000 × g for 5 min
and the supernatants stored at -80 °C. Protein concentration was determined by BCA assay (Pierce) and the absorbance at
562 nm measured by spectrophotometry (NanoDrop ND1000). Samples were separated by SDS-PAGE using 40 μg of protein
per  well  of  NuPAGE Novex  4-12% BIS-TRIS  gels  (Invitrogen)  and  transferred  to  0.2  μm pore  nitrocellulose  membrane
(Amersham) by wet transfer. Over-expression was confirmed by Western blot detection of mouse anti-FLAG (1:1000, Sigma
#F1804), rabbit anti-SMARCA2 (1:1000, Sigma #HPA029981), rabbit anti-SMARCA4 (1:1000, abcam #49360) and rabbit anti-
β-actin (1:25000, Cell Signaling Technology, #4970S) antibodies with goat anti-mouse or donkey anti-rabbit IRDye 800CW
secondary  antibodies  (1:10000,  LI-COR #925-32210  and #926-32213)  using  a  ChemiDoc  MP imaging system (Bio-Rad).
Quantification of band intensity was performed in Image Studio Lite (LI-COR) and normalised to β-actin expression and the
DMSO control.
Ex cell AlphaLISA competition assays
Protein  lysates  containing either  FLAG-tagged SMARCA2 or  SMARCA4,  were utilized for  evaluation of  ternary  complex
formation with full-length protein. Three biological repeats were performed with protein from three separate transfections
and assay wells were ran in duplicate. All assays were performed at room temperature in 384-well alphaplates (PerkinElmer)
with a final assay volume of 30 μL. Before each 1 h incubation, plates were sealed with film (PerkinElmer), centrifuged at
100 × g for 30 s and mixed by shaking at 450 rpm for 2 min. All assay components were made up as 6× stocks in assay buffer
(50 mM HEPES pH 7.5, 100 mM NaCl, 0.1% w/v BSA, 0.02% w/v CHAPS, 0.2 μm filtered). A 12 point, half-log-fold dilution
series was used for all PROTACs and un-tagged VCB. Biotinylated SMARCA probe (4)28 (100 nM final) and excess untagged
VCB (5 μM-50 μM final) or an equivalent volume of assay buffer were incubated with PROTAC (all 0.1 nM-31.62 μM final)
and 15 μg protein lysate or equivalent volume of lysis buffer for 1 h. Anti-FLAG beads (10 μg/mL final, PerkinElmer) were
added  in  low  light  conditions  and  incubated  for  1  h  in  the  dark.  Anti-streptavidin  acceptor  beads  (10  μg/mL  final,
PerkinElmer) were added in low light conditions and incubated for 1 h in the dark. Plates were read on a PHERAstar FS (BMG
LABTECH) with an AlphaLISA optic module (BMG LABTECH, excitation 680 nm and emission 615 nm). Signal intensity was
plotted against PROTAC concentration in GraphPad Prism 7. Data was normalised to the average DMSO signal intensity for
binary (without VCB) and ternary (with VCB) values and the percentage signal  plotted with an [inhibitor]  vs.  response
variable slope four parameter fit with a bottom constraint equal to zero. The binary IC 50 was divided by the ternary IC50 to
generate the α value.
SPR binding studies
SPR experiments were performed on Biacore 8K or T200 instruments (GE Healthcare). Immobilization of target protein was
carried out at 25 °C on a CM5 chip using amine coupling (EDC/NHS, GE Healthcare or XANTEC) in HBS-P+ running buffer,
containing 2 mM TCEP, pH 7.4. Following activation of the surface with EDC/NHS (contact time 600 s, flow rate 10 L/min),
the target bromodomains (SMARCA2BD, SMARCA4BD prepared at 0.5 - 0.7 mg/mL or PBRM1BD5 at 0.005 mg/mL in coupling
buffer consisting of 10 mM Na-Acetate pH 6.5, 0.005% Tween-20 and 50 µM PFI-3 24, were coupled to a density of 1000-
20000 Response Units (RU) (SMARCA2BD and SMARCA4BD) or 100-2000 RU (PBRM1BD5). Surfaces were deactivated using 1 M
ethanolamine. For VHL target protein, streptavidin (Sigma Aldrich) (prepared at 1 mg/mL in 10 mM sodium acetate coupling
buffer,  pH 5.0) was first immobilized by amine coupling to a density of  1000-10000 RU),  after which biotinylated VCB
complex (2.8 M in running buffer) was streptavidin-coupled to a density of 1000-20000 RU. Biotinylated VCB was prepared
as  previously  described7.  The  reference  surface  consisted  of  an  EDC/NHS-treated  surface  deactivated  with  1  M
ethanolamine.
All interaction experiments were performed at 6 °C in running buffer containing 20 mM TRIS, 150 mM potassium chloride, 2
mM magnesium chloride,  2 mM TCEP,  0.005% TWEEN 20,  1% dimethyl  sulfoxide;  pH 8.3.  Sensorgrams from reference
surfaces and blank injections were subtracted from the raw data prior to data analysis using Biacore T200 or Biacore 8K
evaluation software. Sensorgrams recorded at different compound concentrations in multi-cycle experiments were fitted
using a 1:1 interaction model, with a term for mass-transport included.
Proliferation assays
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1000  cells/well  were  seeded  in  384  well  plates.  After  overnight  incubation,  compounds  were  added  to  the  cells  at
logarithmic dose series using the HP Digital Dispenser D300 (Tecan), normalising for added DMSO. 1 day and 8 days after
seeding, cellular ATP content was measured using CellTiterGlo (Promega). Measurements after 8 days were divided by the
measurement after 1 day (=i.e. the T0 plate) to derive fold proliferation.
For online analysis of cell growth, 80000 cells in 800 µL/well were seeded in clear 12-well plates (costar #3513). IncuCyte
Caspase-3/7 Green Apoptosis Assay Reagent (1:1000, Essen BioScience #4440) was added and cells were incubated at 37 °C
and 5% CO2 overnight. On the next day, compounds were added at the desired concentration using the hp digital dispenser
D300 and plates were read in an Incucyte ZOOM. Every 2 h, phase object confluence (percent area) for proliferation and
green object confluence (percent area) for apoptosis were measured. Values for apoptosis were normalised for the number
of cells by dividing the percent area for apoptosis by the percent area for proliferation and multiplying by 1000.
Protein degradation assays
For capillary electrophoresis, 20000 cells in 300 µl/well were seeded in a 24 well plate and incubated at 37 °C overnight.
Compounds were added from DMSO stock solution using a Digital Dispenser D300 (Tecan), normalising for added DMSO and
cells were incubated at 37 °C for the indicated times. Medium was removed, cells washed with PBS and lysed in 80 µl lysis
buffer (1% Triton, 350 mM KCl, 10 mM TRIS pH 7.4, phosphatase-protease inhibitor cocktail (Thermo Scientific #1861281),
10 mM DTT, Benzonase 0.5 µL/mL (Novagen #70746 10KU, 25 U/µL)) for 30 min on ice before insoluble debris was pelleted
by centrifugation. SMARCA2 levels were determined on a WES capillary electrophoresis instrument (Proteinsimple) using
rabbit anti-SMARCA2 antibody (1:25, Sigma #HPA029981), SMARCA4 antibody (CellSignaling #49360, 1:25), PBRM1 antibody
(Bethyl #A301-591A-M, 1:40) and anti-GAPDH antibody (1:100, abcam #ab9485) for normalization. 
For Western blots, 3-4 x 105 NCI-H1568 cells in 2 mL/well were seeded into 6 well plates and 5 x 106 Mv-4-11 cells in 10
mL/plate were seeded into 10 cm plates 24 h before treatment. For two biological replicates, cells were treated for the
indicated times, washed with PBS and lysed with lysis buffer (1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 50 mM Tris pH
7.4, protease inhibitor cocktail (Roche), 50 units/mL benzonase nuclease (Sigma)). NCI-H1568 cells were lysed in 80 µL lysis
buffer/well and Mv-4-11 cells were lysed in 250 µL/plate. Lysates were sonicated then cleared by centrifugation at 4 °C, at
15800 × g for 10 min and the supernatants stored at -20 °C. Protein concentration was determined by BCA assay (Pierce)
and the absorbance at 562 nm measured by spectrophotometry (NanoDrop ND1000). Samples were separated by SDS-PAGE
using  40  μg  of  protein  per  well  of  NuPAGE  Novex  4-12%  BIS-TRIS  gels  (Invitrogen)  and  transferred  to  0.2  μm  pore
nitrocellulose membrane (Amersham) by wet transfer. Western blot images were obtained through detection of rabbit anti-
SMARCA2 (1:1000,  Sigma #HPA029981),  rabbit  anti-SMARCA4 (1:1000,  abcam #ab108318),  rabbit  anti-PBRM1 (1:1000,
Bethyl  Laboratories #A301-591A-M) and rabbit anti-β-actin (1:25000, Cell  Signaling Technology #4970S) antibodies with
donkey anti-rabbit IRDye 800CW secondary antibody (1:10000, LI-COR #926-32213) using a ChemiDoc MP imaging system
(Bio-Rad).
Specificity of antibody detection was determined by the absence of the protein band in cells  that did not express the
respective protein.
PARP cleavage
PARP cleavage was detected by Western blotting using an anti PARP antibody (cell signaling #9542).
Expression constructs for studies with NCI-H1703 and NCI-H1568 cell lines
The coding sequences of SMARCA2 were expressed from the retroviral plasmid LMH, a version of the vector LMN52 in which
the neomycin resistance gene had be replaced by hygromycin resistance using the BClII  and MluI sites for cloning.  To
inactivate the bromodomain, the conserved asparagine 1482 was mutated to alanine.
MS proteomics.
Sample preparation. MV-4-11 cells in RPMI 1640 (Invitrogen) were seeded at 5 × 106 cells on a 100 mm plate 24 h before
treatment. Cells were treated in triplicate by addition of test compound. After 8 h, the cells were centrifuged at 250 × g
for 5 min and washed twice with 12 mL of cold PBS. Cells were lysed in 500 µL of 100 mM TRIS pH 8.0, 4% (w/v) SDS
supplemented with protease inhibitor cocktail (Roche). The lysate was pulse sonicated briefly and then centrifuged at
15,000 × g for 10 min at 4 °C. Samples were quantified using a micro BCA protein assay kit (Thermo Fisher Scientific)
and  200  μg  of  each  sample  was  processed  and  digested  using  the  filter  aided  sample  preparation  (FASP)  method
followed by alkylation with iodoacetamide and digestion with trypsin as previously described 7. The samples were then
desalted using a 7 mm, 3 mL C18 SPE cartridge column (Empore,  3M) and labelled with TMT 10plex Isobaric Label
Reagent Set (Thermo Fisher Scientific) as per the manufacturer's instructions. After labelling, the peptides from the 9
samples were pooled together in equal proportion. The pooled sample was fractionated using high pH reverse-phase
chromatography on an XBridge peptide BEH column (130 Å, 3.5 μm, 2.1 × 150 mm, Waters) on an Ultimate 3000 HPLC
system (Thermo Scientific/Dionex). Buffers A (10 mM ammonium formate in water, pH 9) and B (10 mM ammonium
formate in 90% acetonitrile, pH 9) were used over a linear gradient of 5% to 60% buffer B over 60 min at a flow rate of
200 μL/min. 80 fractions were collected before concatenation into 20 fractions based on the UV signal of each fraction.
All the fractions were dried in a Genevac EZ-2 concentrator and resuspended in 1% formic acid for MS analysis.
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nLC-MS/MS analysis. The fractions were analyzed sequentially on a Q Exactive HF Hybrid Quadrupole-Orbitrap Mass
Spectrometer  (Thermo  Scientific)  coupled  to  an  UltiMate  3000  RSLCnano  UHPLC  system  (Thermo  Scientific)  and
EasySpray column (75 μm × 50 cm, PepMap RSLC C18 column, 2 μm, 100 Å, Thermo Scientific). Buffers A (0.1% formic
acid in water) and B (0.08% formic acid in 80% acetonitrile) were used over a linear gradient from 5% to 35% buffer B
over  125  min  at  300  nL/min.  The  column  temperature  was  50  °C.  The  mass  spectrometer  was  operated  in  data
dependent mode with a single MS survey scan from 335-1600 m/z followed by 15 sequential m/z dependent MS2 scans.
The 15 most intense precursor ions were sequentially fragmented by higher energy collision dissociation (HCD). The
MS1 isolation window was set to 0.7 m/z and the resolution set at 120,000. MS2 resolution was set at 60,000. The AGC
targets for MS1 and MS2 were set at 3e6 ions and 1e5 ions, respectively. The normalized collision energy was set at 32%.
The maximum ion injection times for MS1 and MS2 were set at 50 ms and 200 ms respectively. The data for Compounds
3 and 4 were obtained using a Q Exactive HF-X Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Scientific)
using an MS2 resolution of 45,000.
Peptide and protein identification.  The raw MS data files for all  20 fractions were merged and searched against the
Uniprot-sprot-Human-Canonical database by Maxquant software 1.6.0.16 for protein identification and TMT reporter
ion quantitation. The Maxquant parameters were set as follows: enzyme used Trypsin/P; maximum number of missed
cleavages  equal  to  two;  precursor  mass  tolerance  equal  to  10 p.p.m.;  fragment  mass  tolerance  equal  to  20 p.p.m.;
variable  modifications:  oxidation  (M),  acetyl  (N-term),  deamidation  (NQ),  Gln  ->  pyro-Glu  (Q  N-term);  fixed
modifications: carbamidomethyl (C). The data was filtered by applying a 1% false discovery rate followed by exclusion of
proteins with less than two unique peptides. Quantified proteins were filtered if the absolute fold-change difference
between the three DMSO replicates was ≥ 1.5.
Immunoprecipitation-Mass Spectrometry (IP-MS)
MV-4-11 cells in RPMI 1640 (Invitrogen) at ~1 × 106 cells/mL were treated with 0.1% DMSO, 1 µM ACBI2 or 1 µM cis-ACBI2
for 8 h and 18 h. Treatment was performed as three biological repeats and administered to pooled cells which were then
seeded into separate flasks for each time point. At the indicated time points, cells were centrifuged at 250 × g for 5 min,
washed with PBS and centrifuged again. Cell pellets were snap frozen and stored at -80 °C. Each IP 2 µg anti-SMARCA2
antibody (Santa Cruz, sc-17838x) or 1 µg anti-ARID1A antibody (SIGMA, HPA005456) was DMP-crosslinked to Dynabeads
Protein G or A (Invitrogen, 10004D and 10002D, respectively). Mouse or rabbit IgG was used to establish specificity of the
bait antibody as shown in the supplementary figure 7. Cells were lysed on ice in buffer containing 50 mM TRIS HCl pH 7.5,
150 mM NaCl, 0.5% C7BzO and protease inhibitors for 30 min and spun at 21,000 × g for 15 min at 4 °C. 750 µg of protein
lysate, as determined by Bradford assay (Thermo Scientific), was incubated with crosslinked beads for 4 h at 4 °C. IPs were
washed  three  times  with  50  mM  TRIS  HCl  pH  7.5,  750  mM  NaCl  and  eluted  with  7.5%  SDS,  10  mM  TCEP,  50  mM
triethylammonium bicarbonate buffer pH 8.5 (TEAB) for 20 min at 65 °C. Alkylation was performed for 15 min with 20 mM
iodoacetamide at 25 °C in the dark and proteins were cleaned up using the SP3 (Sera-Mag, VWR) procedure as described
but using 300  µg of stock beads per sample53. Elution was performed in 50 mM TEAB and digestion with 1  µg Trypsin
(Pierce) per sample overnight at 37 °C. Resulting peptides were cleaned up according to the SP3 protocol and eluted into 2%
DMSO in water and vacuum dried. Liquid Chromatography–Mass Spectrometry (LC-MS): Data dependent acquisition was
carried out on the Orbitrap Velos in CID mode. The top 15 precursors were selected for MS2 over the mass range of 335-
1800 (m/z) at a resolution of 60,000. MS2 scans were acquired with a minimum charge state of 2, a normalized collision
energy of 35%, an activation time of 10 ms.  Data searching and analysis: The data were processed using MaxQuant,54
version 1.5.0.25 and the Andromeda search engine with the following parameters55: proteins and peptides were identified
using the human UniProt  database (downloaded on 07.01.2018)  and peptides were searched with  a  fixed cysteine
carbamidomethyl  modification  and  variable  methionine  oxidation  and  N-terminal  acetylation  modifications  and
matched between runs.  T-test differences between means for protein abundance of cells treated with ACBI2 or cis-
ACBI2 were calculated using LFQ intensities and plotted  vs. log 10  P values determined by two-tailed t-test (Perseus
Software1.6.1.3). To test for specificity of IPs, t-test difference of IPs vs. the IgG controls were plotted vs. the log P value
calculated using the means of LFQ intensities.  Each experiment was performed in triplicate except the ARID1A-IP at 8 hr
treatment time which was performed in quadruplicate.
Statistical methods
No statistical methods were used to predetermine sample size, experiments were not randomized, and the investigators
were not blinded to allocation during experiments and outcome assessment. Number of replicates, mean value and error
values are described in the respective figure legends and/or methods. Error bars are show for all data points with replicates
as a measure of variation within the group. All t-tests performed were two-tailed t-tests assuming equal variances.
Data availability
Atomic  coordinates  and  structure  factors  for  new  protein  structures  SMARCA2BD:  (1),  SMARCA2BD:  (2):VCB,
SMARCA2BD:compound  (3):VCB  and  SMARCA4BD:  (3):VCB  have  been  deposited  in  the  Protein  Data  Bank  (PDB)  under
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accession numbers 6HAZ, 6HAY, 6HAX and 6HR2 respectively. All data generated and analyzed during this study are included
in this published article and its supplementary information or are available from the corresponding authors upon reasonable
request.
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